Announcements Trials

Browse Landscape

Phase

Phase 2 7 Phase 1/2 6 Phase 1 5 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 90 Lymphoid 42 Other hematologic neoplasm 6 Myeloid 3 Dermatologic 2 Classical hematology 2 Sarcoma 1 Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 77 Radiotherapy 73 Prednisone 65 Leuprolide 51 Goserelin 49 Gemcitabine 49 Cisplatin 48 bicalutamide 46 enzalutamide 41 Androgen Antagonists 36 pembrolizumab 32 Abiraterone Acetate 30 Mitomycin 29 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28 Magnetic Resonance Spectroscopy 28 Carboplatin 27 Flutamide 25 Triptorelin Pamoate 23 Sunitinib 23 Nivolumab 23 Radiation 22 apalutamide 21 Doxorubicin 20 darolutamide 18 Gonadotropin-Releasing Hormone 18 cabozantinib 16 abiraterone 16 Specimen Handling 16 Radiosurgery 16 Paclitaxel 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lenalidomide × Genitourinary × Clear all

NCT00988208 2018-04-04

Mainsail

Celgene

Phase 3 Completed

1,059 enrolled 27 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡